Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML

NCT07490288 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

AML

Interventions

DRUG: Venetoclax
DRUG: Azacitidine
DRUG: Liposomal Mitoxantrone
DRUG: Cytarabine
PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Sponsor

Institute of Hematology & Blood Diseases Hospital, China